Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Blood Advances|March 2, 2021
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYALale Kostakoglu, Maurizio Martelli, Laurie H Sehn, et al.Blood|January 9, 2019
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCLMagdalena Klanova, Laurie H Sehn, Isabelle Bence-Bruckler, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2017
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell LymphomaUmberto Vitolo, Marek Trněný, David Belada, et al.Clinical Lymphoma, Myeloma & Leukemia|December 11, 2020
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor PrognosisElizabeth Punnoose, Franklin V Peale, Edith Szafer-Glusman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)Christian Kurzeder, Isabel Bover, Frederik Marmé, et al.Blood Advances|July 29, 2021
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphomaJonathan C Strefford, Malgorzata Nowicka, Chantal E Hargreaves, et al.Blood Advances|July 29, 2021
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatmentMalgorzata Nowicka, Laura K Hilton, Margaret Ashton-Key, et al.Pageof 2